3
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T6351 | MGCD-265 analog | MGCD-265,Glesatinib | Apoptosis , VEGFR , c-Met/HGFR |
MGCD-265 analog (Glesatinib) is an orally bioavailable multitargeted tyrosine kinase inhibitor with potential antineoplastic activity with IC50 of 29 nM and 10 nM for c-Met and VEGFR2, respectively. | |||
T15384 | Glesatinib | MGCD265 | c-Met/HGFR |
Glesatinib is an orally active and potent dual inhibitor of MET/SMO. Glesatinib is also a tyrosine kinase inhibitor. It antagonizes P-glycoprotein mediated multidrug resistance (MDR) in NSCLC. | |||
T15383 | Glesatinib hydrochloride | MGCD265 hydrochloride | c-Met/HGFR |
Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET/SMO. Glesatinib hydrochloride is also a tyrosine kinase inhibitor. It antagonizes P-glycoprotein mediated multidrug resistance (MDR) in NSCLC. |